You just read:

Marathon Pharmaceuticals Presents Analyses at AAN of a Phase III Clinical Study of Deflazacort in Patients with Duchenne Muscular Dystrophy (DMD)

News provided by

Marathon Pharmaceuticals, LLC

19 Apr, 2016, 07:43 ET